{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:37:36Z","timestamp":1779183456783,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.thromres.2013.12.008","type":"journal-article","created":{"date-parts":[[2013,12,7]],"date-time":"2013-12-07T19:01:10Z","timestamp":1386442870000},"page":"190-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation"],"prefix":"10.1016","volume":"133","author":[{"given":"Joseph A.","family":"Jakubowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stipo","family":"Jurcevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Richard","family":"Lachno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Andrew L.","family":"Frelinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neehar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Howard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy G.","family":"Mant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2013.12.008_bb0155","author":"World Health Organization"},{"key":"10.1016\/j.thromres.2013.12.008_bb0010","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2146\/ajhp090229","article-title":"Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: A review of the literature","volume":"67","author":"Charneski","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.thromres.2013.12.008_bb0015","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(97)07330-3","article-title":"Sickle-cell disease","volume":"350","author":"Serjeant","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2013.12.008_bb0020","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199904013401307","article-title":"Management of sickle cell disease","volume":"340","author":"Steinberg","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.12.008_bb0025","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/01.ATV.0000220374.00602.a2","article-title":"Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation","volume":"26","author":"Lee","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2013.12.008_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2007.06740.x","article-title":"Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability","volume":"139","author":"Ataga","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2013.12.008_bb0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00001721-199104000-00018","article-title":"Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion","volume":"2","author":"Francis","year":"1991","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.thromres.2013.12.008_bb0040","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.amjmed.2003.07.011","article-title":"Hypercoagulability in sickle cell disease: a curious paradox","volume":"115","author":"Ataga","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.thromres.2013.12.008_bb0045","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0022-2143(97)90005-6","article-title":"Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia","volume":"129","author":"Wun","year":"1997","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.thromres.2013.12.008_bb0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1527-3466.2007.00027.x","article-title":"Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile","volume":"25","author":"Jakubowski","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.thromres.2013.12.008_bb0055","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1046\/j.1365-2141.2000.02353.x","article-title":"Platelet and leucocyte activation in childhood sickle cell disease: association with nocturneal hypoxaemia","volume":"111","author":"Inwald","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2013.12.008_bb0060","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1067\/mlc.2001.115450","article-title":"Thrombogenesis in sickle cell disease","volume":"137","author":"Tomer","year":"2001","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.thromres.2013.12.008_bb0065","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.2830310404","article-title":"Platelet activation during pain crisis in sickle cell anemia patients","volume":"31","author":"Beurling-Harbury","year":"1989","journal-title":"Am J Hematol"},{"key":"10.1016\/j.thromres.2013.12.008_bb0070","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-0038-1661088","article-title":"A double-blind trial of ticlopidine in sickle cell disease","volume":"51","author":"Semple","year":"1984","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.12.008_bb0075","first-page":"199","article-title":"Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises","volume":"15","author":"Cabannes","year":"1984","journal-title":"Agents Actions Suppl"},{"key":"10.1016\/j.thromres.2013.12.008_bb0080","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/0091270010367429","article-title":"Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent","volume":"51","author":"Small","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2013.12.008_bb0085","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1160\/TH07-09-0575","article-title":"The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration","volume":"99","author":"Jakubowski","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.12.008_bb0160","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/bcp.12042","article-title":"A Phase 1 Study of Prasugrel in Patients with Sickle Cell Disease: Pharmacokinetics and Effects on ex Vivo Platelet Reactivity","volume":"75","author":"Jakubowski","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2013.12.008_bb0095","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1111\/j.1538-7836.2005.01603.x","article-title":"Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity","volume":"3","author":"Barnard","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.12.008_bb0100","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1160\/TH07-01-0010","article-title":"The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin","volume":"98","author":"Frelinger","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.12.008_bb0105","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1067\/mhj.2001.119128","article-title":"Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab","volume":"142","author":"Furman","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2013.12.008_bb0110","series-title":"Platelets","first-page":"581","article-title":"Flow Cytometry","author":"Berny-Lang","year":"2012"},{"key":"10.1016\/j.thromres.2013.12.008_bb0115","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0022-3565(24)34895-5","article-title":"Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects","volume":"290","author":"Panara","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.thromres.2013.12.008_bb0120","doi-asserted-by":"crossref","first-page":"10952","DOI":"10.1016\/S0021-9258(19)86616-4","article-title":"The contribution of bovine Factor V and Factor Va to the activity of prothrombinase","volume":"254","author":"Nesheim","year":"1979","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2013.12.008_bb0125","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1189\/jlb.0806510","article-title":"The CD14+ CD16+ blood monocytes: their role in infection and inflammation","volume":"81","author":"Ziegler-Heitbrock","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.thromres.2013.12.008_bb0130","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2007.02838.x","article-title":"The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities","volume":"6","author":"Frelinger","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.12.008_bb0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-8722-6-17","article-title":"A Double-Blind, Randomized, Multicenter Phase 2 Study of Prasugrel versus Placebo in Adult Patients with Sickle Cell Disease","volume":"6","author":"Wun","year":"2013","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.thromres.2013.12.008_bb0140","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.12.008_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.1175","article-title":"Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study","volume":"68","author":"Schnog","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1016\/j.thromres.2013.12.008_bb0150","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.1995.tb05607.x","article-title":"Statius van Eps LW. Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment?","volume":"90","author":"Wolters","year":"1995","journal-title":"Br J Haematol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813005732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813005732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T03:16:11Z","timestamp":1746069371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384813005732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0049384813005732"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2013.12.008","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2013.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}